An open white Velsipity bottle

An open white Velsipity bottle

Introducing

VELSIPITY

For adults with moderate to severe ulcerative colitis (UC)

Discover VELSIPITY, a new FDA-approved
once-daily pill for the treatment of
moderately to severely active UC in adults

VELSIPITY is not an infusion or an injection. It’s also not a steroid or a biologic. If other treatments like 5-
ASAs aren’t working well enough* for you, ask your doctor about VELSIPITY.

*In VELSIPITY studies, adult subjects with moderately to severely active ulcerative colitis had an inadequate response, loss of response, or intolerance to
one or more of the following treatment options: oral aminosalicylates, corticosteroids, thiopurines, Janus kinase (JAK) inhibitors, or biologics prior to
enrollment.

A group of white Velsipity bottles on a turquoise background

A group of white Velsipity bottles on a turquoise background

VELSIPITY was studied in a 52-week trial

There were 408 adults living with moderate to severe UC who had tried other medicines for UC that did not work well enough1

Participants were selected at random to take either VELSIPITY or a placebo for the entirety of the trial. Participants were permitted to continue taking stable doses of oral aminosalicylates and/or oral corticosteroids.1

1In VELSIPITY studies, adult subjects with moderately to severely active ulcerative colitis had an inadequate response, loss of response, or intolerance to one or more of the following treatment options: oral aminosalicylates, corticosteroids, thiopurines, Janus kinase (JAK) inhibitors, or biologics prior to enrollment.

At 12 weeks, 27% of patients (n=75/274) achieved clinical remission* on VELSIPITY vs 7% of patients (n=10/134) on placebo

  • VELSIPITY
  • Placebo

*Clinical remission was defined as stool frequency subscore of 0 (or 1 with a ≥1-point decrease from baseline), rectal bleeding subscore of 0, and endoscopy score ≤ 1 (excluding friability).

At 52 weeks, 32% of patients (n=89/274) achieved clinical remission* on VELSIPITY vs 7% on placebo (n=9/134)

  • VELSIPITY
  • Placebo

*Clinical remission was defined as stool frequency subscore of 0 (or 1 with a ≥1-point decrease from baseline), rectal bleeding subscore of 0, and endoscopy score ≤ 1 (excluding friability).

The safety of VELSIPITY was evaluated in 2 randomized, double-blind, placebo-controlled clinical trials.

Patients taking VELSIPITY may have an increased risk of infections and bradyarrhythmia (slow heart rate) in addition to other potential serious adverse events. See the Important Safety Information or Medication Guide for more information.

The most common side effects (>5%) were headache, elevated liver tests, and dizziness. These are not all the possible side effects of VELSIPITY.

If you're looking for another way to treat UC, ask your doctor about VELSIPITY.

Getting started with VELSIPITY

Before you start treatment with VELSIPITY, your doctor will request a few screening tests. You and your doctor will decide if these tests will happen in the doctor's office or at your home.

Before starting VELSIPITY

Blood work

Complete blood count (CBC), including lymphocyte count and liver function tests.

Before starting VELSIPITY

ECG

An initial ECG (electrocardiogram) to rule out any pre-existing heart conditions you might not know about.

Near the start of your treatment

Eye & skin exams

Baseline exams to monitor any changes in your skin and eye health throughout your treatment.

It is also important to:

  • Review vaccination records to ensure immunizations are up to date with current guidelines.
  • Review list of current or prior medication, vitamins, and herbal supplements to discuss with your doctor prior to starting treatment.

Download a printable guide to help you get started on VELSIPITY.

Download Guide

Velsipityforme logo

Support and savings to help eligible patients get started on treatment

Learn More

Pay as little as $0 per
month for your
VELSIPITY prescription

A Pfizer Velsipity co-pay savings program membership card

As part of our Copay Savings Program, eligible commercially insured patients may pay as little as $0 in out-of-pocket costs, with a maximum benefit of $16,000 per calendar year. See Terms and Conditions.

Save Now

Eligibility required. Commercially insured patients only. The maximum prescription benefit offer per patient is $16,000 per calendar year. Patients enrolled in a state or federally funded prescription health insurance program are not eligible. No membership fees. This is not health insurance. Available only to patients who have been diagnosed with an FDA-approved indication for VELSIPITY. Terms and Conditions apply.

A PfizeVelsipity co-pay savings program membership card

Stay informed
about VELSIPITY*

*Information provided through email
subscription is only related to VELSIPITY, further
information may be required for personalized
financial support.

All fields required.

For questions to ask your doctor and more information about VELSIPITY.

Download Patient Brochure